Multitude Therapeutics Congratulates Partner OnCusp Therapeutics on Positive Phase 1b Data for CUSP06

OnCusp Therapeutics, a partner of Multitude Therapeutics, recently presented data from the Phase 1b study of CUSP06 in platinum-resistant ovarian cancer (PROC) at IGCS (international gynecologic cancer society) annual meeting2026. CUSP06 is a Cadherin-6 targeting Antibody-Drug Conjugate (CDH6 ADC). In the Phase 1b PROC cohort, ORR(Overall Response Rate) was 13/21 (62%) at 4.0 mg/kg; Among patients in Phase 1a and Phase 1b who had previously been treated with mirvetuximab soravtansine, the ORR was 53% (16/30). (Efficacy data cut-off: 23 September 2026.. The safety profile was consistent with other TOP1-inhibitor ADCs, with manageable GI and hematologic toxicities as the most common TRAEs

OnCusp obtained the exclusive global rights (outside of Greater China) to lead the development and commercialization of CUSP06 from Multitude Therapeutics in 2022. In February 2025, OnCusp announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track Designation (FTD) to CUSP06 for the treatment of patients with platinum-resistant ovarian cancer (PROC). Fast Track Designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.

CUSP06, discovered by Multitude Therapeutics, is a novel anti-CDH6 antibody-drug conjugate with a topoisomerase I inhibitor payload (exatecan) and DAR of 8. CUSP06 demonstrated promising clinical activity in PROC, including complete responses. These data support continued development of CUSP06 in PROC.

As the licensor of the program, we extend our warmest congratulations to OnCusp! Multitude Therapeutics looks forward to this innovative ADC benefiting cancer patients worldwide.

Note: CUSP06 is an investigational product and has not been approved in any country or region. The data cited were presented by OnCusp Therapeutics at IGCS 2026 and continue to mature. This article does not constitute medical advice.

About Multitude Therapeutics

Multitude Therapeutics is a clinical-stage company focused on the development of ADC therapeutics. The company employs two technology platforms: MabArray, an antibody platform for the discovery of novel cell-surface oncology targets that enables the pursuit of first-in-class targets; and PAD, a molecular design platform that serves as the backbone of the company’s R&D technology, integrating a clear understanding of tumor biology and existing treatment options with years of experience in ADC design. For identified therapeutic targets in selected indications, this platform supports the rational structural design of ADCs to achieve precise tumor targeting, potent cytotoxicity and minimal off-target effects. The combination of MabArray and PAD generates significant synergy, enabling Multitude Therapeutics to build an ADC “atlas” with the potential to treat malignancies of high unmet medical need and to achieve deeper and more durable responses. Building on these platforms, the company currently has several ADC programs in development, including three programs directed at potential first-in-class targets. Multiple ADC programs, including those against all potential novel targets, have entered clinical development and have demonstrated favorable safety and efficacy, providing initial validation of the company’s platform technologies.